ProteoGenix’ vision for the future is to utilize nucleic acid-based molecular technologies and proteomic biomarkers in the development and commercialization of effective, minimally invasive diagnostics that allow earlier, more accurate and more comprehensive identification and management of intraamniotic infection, neonatal sepsis, preterm birth and other significant complications of pregnancy and the neonate. By enabling improved diagnosis and management of critical maternal/fetal/neonatal conditions, ProteoGenix diagnostic tools will improve clinical outcomes and reduce overall costs to the healthcare system.